uniQure N.V.

uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~

~ None of the Patients Received Factor Infusions, Experienced Any Reported Bleeding Events or Required Immunosuppression Over a Combined 24 Weeks of Observation ~

~ Company R&D Day Scheduled for Monday, November 19 at 8:30 a.m. EST ~

https://finance.yahoo.com/news/uniqure-a...ccounter=1



QURE +48 %

hat sich prächtig entwickelt: